Barbara E Power
Overview
Explore the profile of Barbara E Power including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
597
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rosenes Z, Mulhern T, Hatters D, Ilag L, Power B, Hosking C, et al.
PLoS One
. 2012 Oct;
7(9):e44927.
PMID: 23028685
The monoclonal IgM antibody PAT-SM6 derived from human tumours induces apoptosis in tumour cells and is considered a potential anti-cancer agent. A primary target for PAT-SM6 is the unfolded protein...
2.
Jachimowicz R, Fracasso G, Yazaki P, Power B, Borchmann P, Engert A, et al.
Mol Cancer Ther
. 2011 Apr;
10(6):1036-45.
PMID: 21525185
Cancer that might develop as host natural killer (NK) cells fail to detect ligands for their activating NK receptors. Immunoligands represent promising immunotherapeutic tools to overcome this deficit. These are...
3.
Rothe A, Power B, Hudson P
Nat Clin Pract Rheumatol
. 2008 Sep;
4(11):605-14.
PMID: 18813220
Antibody engineering and protein design have led to the creation of a new era of targeted anti-inflammatory therapies in rheumatology. Recombinant DNA technologies have enabled the selection and humanization of...
4.
Kelly M, Lee F, Tahtis K, Power B, Smyth F, Brechbiel M, et al.
Cancer Biother Radiopharm
. 2008 Sep;
23(4):411-23.
PMID: 18771345
The use of single-chain variable fragment (scFv) constructs has been investigated in cancer radioimmunotherapy (RIT) and radioimmunodetection, as these molecules permit rapid tumor penetration and clearance from the serum relative...
5.
Zhu Y, Power B
Adv Biochem Eng Biotechnol
. 2008 Jul;
110:81-114.
PMID: 18594785
In vitro compartmentalization (IVC) is a powerful tool for studying protein-protein reactions, due to its high capacity and the versatility of droplet technologies. IVC bridges the gap between chemistry and...
6.
Rothe A, Nathanielsz A, Oberhauser F, von Pogge S, Engert A, Hudson P, et al.
Biol Chem
. 2008 Jan;
389(4):433-9.
PMID: 18225987
Novel in vitro methods for the display of antibody libraries against disease-related antigens have led to the development of powerful protein-based biotherapeutics. Eukaryotic ternary ribosome complexes can be used to...
7.
Rothe A, Nathanielsz A, Hosse R, Oberhauser F, Strandmann E, Engert A, et al.
J Biotechnol
. 2007 Jul;
130(4):448-54.
PMID: 17604868
Engineered antibodies have become an invaluable source of biopharmaceuticals against a wide range of diseases. About 200 antibody-based biologicals have been tested in clinical trials. Single chain variable fragments of...
8.
Rothe A, Surjadi R, Power B
Trends Biotechnol
. 2006 Oct;
24(12):587-92.
PMID: 17055094
IVC (in vitro compartmentalization) provides a complete cell-free approach for the production of novel targeted proteins. IVC uses aqueous droplets, which contain DNA and components for protein production, within water-in-oil...
9.
Wilson A, Power B, Molloy P
Biochim Biophys Acta
. 2006 Oct;
1775(1):138-62.
PMID: 17045745
Changes in human DNA methylation patterns are an important feature of cancer development and progression and a potential role in other conditions such as atherosclerosis and autoimmune diseases (e.g., multiple...
10.
Rothe A, Hosse R, Power B
FASEB J
. 2006 Jul;
20(10):1599-610.
PMID: 16873883
Display technologies are fundamental to the isolation of specific high-affinity binding proteins for diagnostic and therapeutic applications in cancer, neurodegenerative, and infectious diseases as well as autoimmune and inflammatory disorders....